Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894368 | 0.81 | VCAM1 (0.47) | RAB9ATSHRTDP1POLBMAPT | |
| SCHEMBL14290261 | 0.77 | ADORA1 (0.34) | ALDH1A1TDP1MEN1KMT2ALMNA | |
| SCHEMBL11649742 | 0.77 | TDP1 (0.43) | RAB9ATSHRALDH1A1TDP1POLB | |
| SCHEMBL3144948 | 0.75 | HSD17B10 (0.41) | RAB9ATSHRALDH1A1TDP1POLB | |
| SCHEMBL9516753 | 0.74 | HTT (0.43) | RAB9AALDH1A1POLBMEN1MAPT | |
| SCHEMBL3145085 | 0.74 | RAB9A (0.39) | RAB9AALDH1A1TDP1POLBMAPT | |
| SCHEMBL12972546 | 0.73 | ALDH1A1 (0.41) | RAB9ATSHRALDH1A1TDP1POLB | |
| SCHEMBL3143576 | 0.73 | RAB9A (0.39) | RAB9AALDH1A1TDP1POLBMEN1 | |
| SCHEMBL3141013 | 0.73 | ATM (0.48) | RAB9AALDH1A1TDP1MEN1MAPT | |
| SCHEMBL9314849 | 0.72 | TDP1 (0.42) | RAB9ATSHRALDH1A1TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309596-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1309596-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-02-06 | — | — | EP | disclosed |
| US-6844435-B2 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20030207902-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1309596-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6489328-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; ANTIPROLIFERATIVE AGENTS; ANTICANCER AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020119975-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002014319-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119975-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, JAK1, LCK | RAB9A 2312/4885TSHR 3220/4885ALDH1A1 1746/4885 |
| US-20030207902-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, JAK1, LCK | RAB9A 2312/4885TSHR 3220/4885ALDH1A1 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.